Detalhe da pesquisa
1.
Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma.
Front Immunol
; 14: 1330635, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38155973
2.
Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
J Mol Diagn
; 25(10): 771-781, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37544359
3.
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Front Immunol
; 14: 1220129, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965317
4.
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.
Asia Pac J Clin Oncol
; 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37415393
5.
Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches.
Cancer Treat Rev
; 98: 102219, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33993033
6.
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
Sci Rep
; 10(1): 17687, 2020 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077847
7.
A meta-analysis of the prevalence of Low Anterior Resection Syndrome and systematic review of risk factors.
Int J Surg
; 56: 234-241, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29936195